Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Esophageal Squamous Cell Carcinoma
- Type
- Interventional
- Phase
- Phase 1Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Both males and females
Description
This study was designed as an open-lable, single-arm, exploratory clinical study. Sintilimab in combination with liposome paclitaxel, cis-platinum and S-1 will be given every 3 weeks to our patients for 2 cycles as neoadjuvant therapy. A radical dissection is scheduled within 6 weeks after last neoa...
This study was designed as an open-lable, single-arm, exploratory clinical study. Sintilimab in combination with liposome paclitaxel, cis-platinum and S-1 will be given every 3 weeks to our patients for 2 cycles as neoadjuvant therapy. A radical dissection is scheduled within 6 weeks after last neoadjuvant treatment. This study will be devided for 3 phases: safety run-in, efficacy pilot and efficacy confirmation.
Tracking Information
- NCT #
- NCT03946969
- Collaborators
- Innovent Biologics (Suzhou) Co. Ltd.
- Investigators
- Principal Investigator: Yanhong Gu The First Affiliated Hospital with Nanjing Medical University
Get Well Soon